PHI with Multiple hereditary exostoses
How does this condition affect your private health insurance?
Kartilaginäre Exostosenkrankheit, also known as Multiple Hereditary Exostoses (MHE), is a genetic disorder characterized by the development of multiple benign bone tumors, called osteochondromas, near the growth plates of long bones. These bony outgrowths can cause pain, restrict joint movement, lead to limb length discrepancies, and nerve compression. While typically benign, there is a small risk of malignant transformation to chondrosarcoma, particularly in adulthood. Management often involves surgical removal of symptomatic exostoses, orthopedic monitoring, and physical therapy to improve function and alleviate discomfort. It's a lifelong condition impacting bone growth and development.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Months to years for initial presentation, diagnosis, and potential first interventions.
Duration of Illness (Lifetime)
Lifelong, requiring ongoing monitoring and potential interventions throughout life.
Cost of Treatment (Initial)
Moderate to high (diagnostic imaging, specialist consultations, possible initial surgical removal of symptomatic exostoses).
Cost of Treatment (Lifetime)
High (multiple surgeries, physical therapy, regular orthopedic monitoring, management of complications over decades).
Mortality Rate
Very low (less than 1% annually, primarily associated with rare malignant transformation to chondrosarcoma).
Risk of Secondary Damages
High (limb deformities, restricted joint movement, chronic pain, nerve compression, vascular compromise, psychosocial impact).
Probability of Full Recovery
Low (the genetic condition and presence of exostoses are permanent; however, symptoms can often be managed effectively).
Underlying Disease Risk
Low (MHE is typically a primary genetic disorder; other unrelated underlying diseases are not specifically more probable).